There are 2789 resources available
670P - Cabozantinib associated with concomitant radiotherapy or a bone targeted agent (multimodal approach, results from the CABOREAL study post-hoc analysis)
Presenter: Marine Gross-Goupil
Session: ePoster Display
671P - Patient-reported experience of diagnosis, management, and burden of renal cell carcinomas: Results from the 2020 Global Patient Survey from 41 countries
Presenter: Rachel Giles
Session: ePoster Display
672P - Real-world study of cabozantinib in patients with advanced renal cell carcinoma (aRCC) after VEGF-targeted therapy (CASSIOPE): Interim data for patients who had received prior nivolumab
Presenter: Giuseppe Procopio
Session: ePoster Display
504P - Prognostic factors of patients with AFP-positive colorectal cancer: A case-control study
Presenter: Min-Yi Lv
Session: ePoster Display
614P - Circulating tumor cell (CTC) morphologic sub-types present prior to treatment in the CARD trial identify therapy resistance
Presenter: J.S. de Bono
Session: ePoster Display
507TiP - PRESERVE 1: A phase III, randomized, double-blind trial of trilaciclib versus placebo in patients receiving FOLFOXIRI/bevacizumab for metastatic colorectal cancer
Presenter: Joleen Hubbard
Session: ePoster Display
676P - CABOPRE: A phase II study of cabozantinib (cabo) prior cytoreductive nephrectomy (CN) in metastatic renal cell carcinoma (mRCC)
Presenter: Guillermo De Velasco
Session: ePoster Display
677P - Immunotherapy vs sunitinib as first-line treatment for advanced renal cell carcinoma in favourable risk patients: A meta-analysis of randomized clinical trials
Presenter: Ray Manneh Kopp
Session: ePoster Display
678P - Cytoreductive nephrectomy (CN) for patients with metastatic sarcomatoid and/or rhabdoid (S/R) renal cell carcinoma (RCC) treated with immune checkpoint inhibitors (ICI)
Presenter: Andrew Hahn
Session: ePoster Display